NanoViricides, Inc. (NYSEAMERICAN:NNVC – Get Rating) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $1.30. NanoViricides shares last traded at $1.25, with a volume of 22,160 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, EF Hutton Acquisition Co. I dropped their target price on shares of NanoViricides from $8.50 to $5.25 and set a “buy” rating on the stock in a research report on Tuesday, February 28th.
NanoViricides Stock Performance
The firm has a market cap of $14.51 million, a price-to-earnings ratio of -2.02 and a beta of 0.93.
Institutional Trading of NanoViricides
Several institutional investors and hedge funds have recently bought and sold shares of NNVC. UBS Group AG lifted its holdings in shares of NanoViricides by 114.5% during the first quarter. UBS Group AG now owns 17,448 shares of the company’s stock worth $37,000 after buying an additional 9,314 shares during the last quarter. Two Sigma Investments LP bought a new position in NanoViricides in the third quarter valued at about $59,000. Millennium Management LLC boosted its holdings in NanoViricides by 59.1% in the fourth quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock valued at $75,000 after acquiring an additional 25,012 shares during the last quarter. Renaissance Technologies LLC lifted its stake in NanoViricides by 18.4% in the third quarter. Renaissance Technologies LLC now owns 71,066 shares of the company’s stock valued at $123,000 after buying an additional 11,066 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of NanoViricides by 7.1% during the third quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock worth $792,000 after purchasing an additional 30,194 shares during the period. Institutional investors and hedge funds own 9.62% of the company’s stock.
NanoViricides, Inc is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R.
- Get a free copy of the StockNews.com research report on NanoViricides (NNVC)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.